## Appendix A: pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

| Name of registered clinician:             | Mary Lynn Savoie                                       |
|---|--|
| Name of drug and indication under review: | Blinatumomab for relapsed or refractory BCP<br>Ph+ ALL |

# **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

## Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
  - X Yes

□ No

If no, please go to Section B

2. What form of payment did you receive? (Check all that apply.)

| Х | Advisory role      | Program or Operating    |
|---|--------------------|-------------------------|
|   | (e.g., advisory    | Funding (e.g., website) |
|   | boards, HTA        |                         |
|   | submission advice) |                         |
|   | Conference         | Research/educational    |
|   | attendance         | grants                  |
|   | Royalties          | Travel grants           |
|   | Gifts              | Sponsorship of Events   |
|   | Honoraria          | Other, please specify:  |

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

| Amgen, \$ |  |  |  |
|-----------|--|--|--|
|           |  |  |  |
|           |  |  |  |

### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

## Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: 07/09/2018\_\_\_\_\_ Name: Mary Lynn Savoie

Signature:

# CADTH

1

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:

Name of drug and indication under review:

munal

### **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

### Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - □ Yes
  - Q NO
  - If no, please go to Section B.

| Conference attendance   Research/educational grants     Royalties   Travel grants     Gifts   Sponsorship of events |
|---|
|   |
| □ Gifts □ Sponsorship of events   |
|   |
| □ Honoraria □ Other, please specify:  |

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Clinician Input Template for CADTH pan-Canadian Oncology Drug Review Program

<sup>2.</sup> What form of payment did you receive? (Check all that apply.)

# CADTH

### Section B: Holdings or Other Interests

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

### Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

К Signature Name



Before completing this template, be sure to register with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

# pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Tom Kouroukis

Name of drug and indication under review: Blinatumomab/ALL

### **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

#### Section A: Payment Received

Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
Yes
No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - Conference attendance
  - Royalties
  - □ Gifts
  - Honoraria
  - Other, please specify: Click here to enter text.
- Please provide the names of companies and organizations and the amounts of the payments in the box below.

X

Roche - Funding to the hospital for dinical trial

Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

1



Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

March 29th, 2018 Date:

Name:

Signature:

Click here to enter text.

pCODR Clinician Input on a Drug Review